Pharmaron Beijing Co (HKSE:03759) Change In Working Capital : HK$0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co Change In Working Capital?

Pharmaron Beijing Co's change in working capital for the quarter that ended in Mar. 2025 was HK$0 Mil.

Pharmaron Beijing Co's change in working capital for the fiscal year that ended in Dec. 2024 was HK$-161 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Pharmaron Beijing Co Change In Working Capital Historical Data

The historical data trend for Pharmaron Beijing Co's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Change In Working Capital Chart

Pharmaron Beijing Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Working Capital

Get a 7-Day Free Trial

278.09

159.23

-386.90

0.04

-160.71

Pharmaron Beijing Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Working Capital	Get a 7-Day Free Trial															-	-	-	-	-

Pharmaron Beijing Co Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Pharmaron Beijing Co Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaron Beijing Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (HKSE:03759) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

300759:China

Address

No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, Hong Kong, HKG

Website

https://www.pharmaron.com

Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.

Executives

Hsbc Holdings Plc	2106 Person having a security interest in shares
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Morgan Stanley	2201 Interest of corporation controlled by you
The Bank Of New York Mellon Corporation	2201 Interest of corporation controlled by you
Citigroup Inc.	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you
Gic Private Limited	2102 Investment manager
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Matthews International Capital Management, Llc	2102 Investment manager
First H Share Award And Scheme Of Pharmaron Beijing Co., Ltd.	2301 Trustee
Kastle Limited	2301 Trustee
Jian Xin Bei Jing Tou Zi Ji Jin Guan Li You Xian Ze Ren Gong Si	2201 Interest of corporation controlled by you
Jian Xin Xin Tuo You Xian Ze Ren Gong Si	2201 Interest of corporation controlled by you

Pharmaron Beijing Co Headlines

No Headlines